openPR Logo
Press release

Ewing Sarcoma Clinical Trials 2024: FDA Approvals, Pipeline, Therapies, ROA, MOA, Companies and Treatment involved by DelveInsight

09-09-2024 08:37 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Ewing Sarcoma Clinical Trials

Ewing Sarcoma Clinical Trials

(Albany, USA) DelveInsight's, "Ewing Sarcoma Pipeline Insights" report provides comprehensive insights about 25+ Ewing Sarcoma companies and 25+ pipeline drugs in the Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ewing Sarcoma Pipeline Report
• DelveInsight's Ewing Sarcoma pipeline report depicts a robust space with 25+ Ewing Sarcoma companies working to develop 25+ pipeline therapies for Ewing Sarcoma treatment.
• The leading Ewing Sarcoma Companies working in the market include Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
• Promising Ewing Sarcoma Pipeline Therapies in the various stages of development includes Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.
• December 2023: St. Jude Children's Research Hospital announced a study of Phase 1 & 2 clinical trials for Onivyde, Talazoparib and Temozolomide. The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm.
• December 2023: Children's Hospital of Philadelphia announced a study of Phase 1 clinical trials for Cabozantinib. The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.
• December 2023: Fusion Pharmaceuticals Inc. announced a study of Phase 1 clinical trials for [225]-FPI-2059 and [111In]-FPI-2058. This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.

Request a sample and discover the recent advances in Ewing Sarcoma Treatment Drugs @ Ewing Sarcoma Pipeline Outlook Report- https://www.delveinsight.com/report-store/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Ewing Sarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ewing Sarcoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ewing Sarcoma clinical trial landscape.

Ewing Sarcoma Overview
Ewing sarcoma is the second most common primary malignant bone tumor, mostly affecting adolescents in the second decade of their life, and it is a highly metastatic class of sarcoma. Despite the use of radiotherapy or surgery, historically, an estimated 85% to 90% of patients died within a few months from a metastasis.

Find out more about Ewing Sarcoma Treatment Landscape @ Drugs for Ewing Sarcoma Treatment- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ewing Sarcoma Emerging Drugs Profile
• Vigil: Gradalis
• ONCT216: Oncternal Therapeutics
• SP-2577: Salarius Pharmaceuticals

Ewing Sarcoma Pipeline Therapeutics Assessment
There are approx. 25+ Ewing Sarcoma companies which are developing the Ewing Sarcoma therapies. The Ewing Sarcoma companies which have their Ewing Sarcoma drug candidates in the most advanced stage, i.e. Phase III include, Gradalis.

DelveInsight's Ewing Sarcoma pipeline report covers around 25+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Ewing Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Ewing Sarcoma Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Learn more about the emerging Ewing Sarcoma Pipeline Therapies @ Ewing Sarcoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Ewing Sarcoma Pipeline Report
• Coverage- Global
• Ewing Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ewing Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Ewing Sarcoma Companies- Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
• Ewing Sarcoma Pipeline Therapies- Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.

Dive deep into rich insights for new drugs for Ewing Sarcoma treatment, Visit @ Ewing Sarcoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Ewing Sarcoma Executive Summary
3. Ewing Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ewing Sarcoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Vigil: Gradalis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ONCT216: Oncternal Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SP-2577: Salarius Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. CLR 131: Cellectar Biosciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ewing Sarcoma Companies
21. Ewing Sarcoma Key Products
22. Ewing Sarcoma Unmet Needs
23. Ewing Sarcoma Market Drivers and Barriers
24. Ewing Sarcoma Future Perspectives and Conclusion
25. Ewing Sarcoma Analyst Views
26. Ewing Sarcoma Key Companies
27. Appendix

For further information on the Ewing Sarcoma pipeline therapeutics, reach out to Ewing Sarcoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/atrial-fibrillation-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/alstrom-syndrome-epidemiology-forecast
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Advanced Recurrent Ovarian Cancer Market: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
• Primary Progressive Multiple Sclerosis Ppms Market: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
• Goitre Market: https://www.delveinsight.com/report-store/goitre-market
• Pharma Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Hemophilia With Inhibitor Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Primoridal Dwarfism Market: https://www.delveinsight.com/report-store/primordial-dwarfism-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-pipeline-insight
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/ventricular-dysfunction-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Ankylosing Spondylitis Bekhterevs Disease Market: https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
• Atrophic Vaginitis Market: https://www.delveinsight.com/report-store/atrophic-vaginitis-market
• Diffuse Cutaneous Systemic Sclerosis Market: https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market
• Idiopathic Membranous Nephropathy Market: https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
• Intrahepatic Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Acute Gout Flare Market: https://www.delveinsight.com/report-store/acute-gout-flare-market
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Chronic Idiopathic Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Crohns Disease Cd Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Helicobacter Pylori Infections Market: https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market
• Juvenile Rheumatoid Arthritis Market: https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-market
• Acromegaly Market: https://www.delveinsight.com/report-store/acromegaly-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Chronic Plaque Psoriasis Market: https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Gastric Neuroendocrine Tumors Market: https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
• Post Traumatic Stress Disorder Market: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ewing Sarcoma Clinical Trials 2024: FDA Approvals, Pipeline, Therapies, ROA, MOA, Companies and Treatment involved by DelveInsight here

News-ID: 3648991 • Views:

More Releases from DelveInsight Business Research

Beta Thalassemia Market Projected to Grow by 2034, Forecasts DelveInsight | Key Players Include Novartis, Merck, Bristol Myers Squibb, Bluebird Bio, CRISPR Therapeutics, and Others
Beta Thalassemia Market Projected to Grow by 2034, Forecasts DelveInsight | Key …
(Albany, USA) DelveInsight's "Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Beta Thalassemia, historical and forecasted epidemiology as well as the Beta Thalassemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Beta Thalassemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Beta Thalassemia
Colorectal Cancer Treatment Drugs, Clinical Trials, and Companies 2024
Colorectal Cancer Treatment Drugs, Clinical Trials, and Companies 2024
DelveInsight's, "Colorectal Cancer Pipeline Insight 2024" report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our comprehensive Colorectal Cancer Pipeline Report to stay informed
Non-Small Cell Lung Cancer Clinical Trials 2024: FDA Approvals, Pipeline, Therapies, Treatment Market, ROA, MOA and Companies involved by DelveInsight
Non-Small Cell Lung Cancer Clinical Trials 2024: FDA Approvals, Pipeline, Therap …
DelveInsight's, "Non-Small-Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 135+ Non-Small Cell Lung Cancer Companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights
Sphingosine 1 Phosphate Receptor (S1PR) Modulators Market Projected for Strong Growth by 2032, Reports DelveInsight | Key Players: Celgene (BMS), Pfizer, Novartis
Sphingosine 1 Phosphate Receptor (S1PR) Modulators Market Projected for Strong G …
(Albany, USA) DelveInsight's Sphingosine 1 Phosphate Receptor (S1PR) Modulators Market Insights report offers a thorough understanding of prevailing treatment protocols, emerging therapies, individual therapy market shares, and the projected market size for Sphingosine 1 Phosphate Receptor (S1PR) Modulators from 2019 to 2032. The market analysis is segmented across the 7MM, encompassing the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan. The Sphingosine 1 Phosphate Receptor

All 5 Releases


More Releases for Ewing

Ewing Sarcoma Market (2019-2028) Overview with Size, Patients Population, Total …
Ewing Sarcoma Market Synopsis: Global Ewing Sarcoma Market Insights, Epidemiology and Market Forecast studies the present scenario of market (with the base year being 2018), Key Cross Competition, and the growth prospects of global Ewing Sarcoma market for 2018-2028 definition of Ewing Sarcoma: Ewing sarcoma is a malignant small, round, blue cell tumor. It is a disease in which cancer cells are found in the bone or in soft tissue. The most common
Ewing Sarcoma Therapeutics - Pipeline Analysis Celgene, Novartis, Pfizer, MacroG …
Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development. Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc. Download free report Sample at: https://www.psmarketresearch.com/market-analysis/ewing-sarcoma-therapeutics-pipeline-analysis/report-sample *Major companies
Research Focused On the Ewing Sarcoma Treatment Market Size & Share, Growth, Tre …
The report "Ewing Sarcoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025 ", has been prepared based on an in-depth market analysis with inputs from industry experts. The objectives of this study are as follows: To define, describe, and forecast the "Ewing Sarcoma Treatment" market by type, application, component, delivery model, end user, and region To provide detailed information regarding major factors influencing market growth (drivers,
Ewing Sarcoma Global Clinical Trials Review H2 2017
Summary: ReportsWeb.com published “Ewing Sarcoma Global Clinical Trials” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: "Ewing Sarcoma Industry Outlook to 2022-Market Forecasts for Liquefied Natural Gas (LNG), Oil Storage, Pipelines and Gas Processing", is a comprehensive report on midstream oil and gas industry in Algeria. The report provides details such as name,
Ewing Sarcoma Global Clinical Trials Status, Region and Phase Review, H2, 2017
To Understand the Pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Ewing Sarcoma Global Clinical Trials Review, H2, 2017, provides an overview of Ewing Sarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Ewing Sarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers
Ewing Sarcoma Global Clinical Market – Growth & Forecast to 2022 Including Key …
A new research document with title 'Ewing Sarcoma Global Clinical Trials Review, H2, 2017' covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions and important players/vendors such as Pharma Mar SA, Pfizer , NantWorks etc. The report will help user gain market insights, future trends and growth prospects of Review, H2, 2017 , “Ewing Sarcoma Global Clinical Trials Review, H2, 2017""